155 related articles for article (PubMed ID: 36606303)
1. Feasibility and safety of neck level IB-sparing radiotherapy in nasopharyngeal cancer: a long-term single institution analysis.
Kim D; Keam B; Ahn SH; Choi CH; Wu HG
Radiat Oncol J; 2022 Dec; 40(4):260-269. PubMed ID: 36606303
[TBL] [Abstract][Full Text] [Related]
2. Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.
Wang G; Huang C; Yang K; Guo R; Qiu Y; Li W; Mao Y; Tang L; Ma J
Radiother Oncol; 2022 Dec; 177():205-213. PubMed ID: 36375564
[TBL] [Abstract][Full Text] [Related]
3. The feasibility analysis of omission of elective irradiation to level IB lymph nodes in low-risk nasopharyngeal carcinoma based on the 2013 updated consensus guideline for neck nodal levels.
Ou X; Miao Y; Wang X; Ding J; He X; Hu C
Radiat Oncol; 2017 Aug; 12(1):137. PubMed ID: 28821277
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and distribution features of level IB lymph nodes metastasis in nasopharyngeal carcinoma.
Zeng L; Zhang Q; Ao F; Jiang CL; Xiao Y; Xie HH; Tang YQ; Gong XC; Li JG
Auris Nasus Larynx; 2019 Jun; 46(3):457-464. PubMed ID: 30528104
[TBL] [Abstract][Full Text] [Related]
5. Sparing level Ib lymph nodes by intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma.
Chen J; Ou D; He X; Hu C
Int J Clin Oncol; 2014 Dec; 19(6):998-1004. PubMed ID: 24337503
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: a retrospective analysis.
Zhang F; Cheng YK; Li WF; Guo R; Chen L; Sun Y; Mao YP; Zhou GQ; Liu X; Liu LZ; Lin AH; Tang LL; Ma J
BMC Cancer; 2015 Oct; 15():709. PubMed ID: 26472233
[TBL] [Abstract][Full Text] [Related]
7. The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline.
Meng Z; Li P; Yang D; Huang H; Dong H; Qin Y; Bin Y; Li R; Wang S; Chen X; Kang M
Radiother Oncol; 2024 Feb; 191():110027. PubMed ID: 38008418
[TBL] [Abstract][Full Text] [Related]
8. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer.
Dawson LA; Anzai Y; Marsh L; Martel MK; Paulino A; Ship JA; Eisbruch A
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1117-26. PubMed ID: 10725621
[TBL] [Abstract][Full Text] [Related]
9. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing.
Eisbruch A; Marsh LH; Dawson LA; Bradford CR; Teknos TN; Chepeha DB; Worden FP; Urba S; Lin A; Schipper MJ; Wolf GT
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):28-42. PubMed ID: 15093896
[TBL] [Abstract][Full Text] [Related]
10. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
[TBL] [Abstract][Full Text] [Related]
11. Selectively sparing the submandibular gland when level Ib lymph nodes are included in the radiation target volume: An initial safety analysis of a novel planning objective.
Varra V; Ross RB; Juloori A; Campbell S; Tom MC; Joshi NP; Woody NM; Ward MC; Xia P; Koyfman SA; Greskovich JF
Oral Oncol; 2019 Feb; 89():79-83. PubMed ID: 30732963
[TBL] [Abstract][Full Text] [Related]
12. Effects of omitting elective neck irradiation to nodal Level IB in nasopharyngeal carcinoma patients with negative Level IB lymph nodes treated by intensity-modulated radiotherapy: a Phase 2 study.
Li M; Huang XG; Yang ZN; Lu JY; Zhan YZ; Xie WJ; Zhou DJ; Wang L; Zhu DX; Lin ZX
Br J Radiol; 2016 Sep; 89(1065):20150621. PubMed ID: 27376590
[TBL] [Abstract][Full Text] [Related]
13. Level IB nodal involvement in oropharyngeal carcinoma: implications for submandibular gland-sparing intensity-modulated radiotherapy.
Yu Y; Daly ME; Farwell DG; Luu Q; Gandour-Edwards R; Donald PJ; Chen AM
Laryngoscope; 2015 Mar; 125(3):608-14. PubMed ID: 25215891
[TBL] [Abstract][Full Text] [Related]
14. Level Ib sparing intensity-modulated radiation therapy in selected nasopharyngeal carcinoma patients based on the International Guideline.
Guo Q; Xiao N; Xu H; Zong J; Xiao Y; Lu T; Xu Y; Wang B; Chen B; Pan J; Lin S
Radiother Oncol; 2022 Feb; 167():239-243. PubMed ID: 34973279
[TBL] [Abstract][Full Text] [Related]
15. Five-year outcomes of sparing level IB in node-positive, human papillomavirus-associated oropharyngeal carcinoma: A safety and efficacy analysis.
Ross RB; Juloori A; Varra V; Ward MC; Campbell S; Woody NM; Murray E; Xia P; Greskovich JF; Koyfman SA; Joshi NP
Oral Oncol; 2019 Feb; 89():66-71. PubMed ID: 30732961
[TBL] [Abstract][Full Text] [Related]
16. Safety of contralateral submandibular gland sparing in locally advanced oropharyngeal cancers: A multicenter review.
Robin TP; Gan GN; Tam M; Westerly D; Riaz N; Karam SD; Lee N; Raben D
Head Neck; 2016 Apr; 38(4):506-11. PubMed ID: 25482748
[TBL] [Abstract][Full Text] [Related]
17. A Prospective Study on Defining the Indications of Prophylactic Level IB Radiotherapy in Nasopharyngeal Carcinoma Based on a Risk Score Model.
Zhang X; Yuan JJ; Ding JW; Zhang SH; Zhang ZL; Hu RH; Gong D; Hu JL; Tu ZW; Zeng L
Oncol Res Treat; 2022; 45(9):471-479. PubMed ID: 35705024
[TBL] [Abstract][Full Text] [Related]
18. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420
[TBL] [Abstract][Full Text] [Related]
19. The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation.
Lee NCJ; Kelly JR; Park HS; Yarbrough WG; Burtness BA; Husain ZA
Pract Radiat Oncol; 2017; 7(5):e317-e321. PubMed ID: 28356201
[TBL] [Abstract][Full Text] [Related]
20. Analysis of rare periparotid recurrence after parotid gland-sparing intensity-modulated radiotherapy for nasopharyngeal carcinoma.
Xu Y; Zhang M; Yue Q; Zong J; Lin J; Sun R; Qiu S; Lin S; Pan J
Cancer Radiother; 2016 Jul; 20(5):377-83. PubMed ID: 27372558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
